Using ChatGPT to educate patients with early-stage liver cancer
Evaluating the Role of ChatGPT in Educating Patients With Early-stage Hepatocellular Carcinoma
This study tests if using a chatbot to provide personalized education can help people with early-stage liver cancer understand their condition and treatment better than just standard education alone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 450 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Taipei Veterans General Hospital, Taiwan Government |
| Locations | 1 site (Taipei, Beitou District) |
| Trial ID | NCT06384950 on ClinicalTrials.gov |
What this trial studies
This research evaluates the effectiveness of a GPT-3.5-based chatbot in providing personalized education to patients diagnosed with early-stage hepatocellular carcinoma. Participants will be divided into two groups: one receiving standard patient education and the other receiving both traditional education and chatbot assistance. The goal is to enhance patient understanding of their condition, treatment options, and long-term outcomes through timely information and support. The study employs a Randomized Controlled Trial design to compare the outcomes of both cohorts.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with early-stage hepatocellular carcinoma (stages 0 to A).
Not a fit: Patients under 18 years old or those currently undergoing treatment for other cancers may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve patient understanding and management of early-stage liver cancer.
How similar studies have performed: While the use of AI chatbots for patient education is a growing field, this specific application in early-stage liver cancer is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with early-stage hepatocellular carcinoma from both gastroenterology and general surgery outpatient departments were included. Early-stage hepatocellular carcinoma is defined based on the Barcelona Clinic Liver Cancer (BCLC) staging as stages 0 to A. Exclusion Criteria: * Patients under the age of 18 or those currently undergoing treatment for other cancers.
Where this trial is running
Taipei, Beitou District
- Taipei Veterans General Hospital — Taipei, Beitou District, Taiwan (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.